LETTER TO THE EDITOR

Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies
Elevated levels of cytokines such as macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6) and interleukin-8 (IL-8) were found in the serum of patients with lymphoid and nonlymphoid malignancies. 1, 2 These molecules are markers of the exacerbation of cytokine production in patients with hematologic malignancies. Leukemia inhibitory factor (LIF) is a pleiotropic inflammatory cytokine identified by its growth and differentiation activities on hematopoietic cells. [3] [4] [5] Human mesenchymal cells and T cells produce LIF spontaneously or after induction.
6,7 LIF and IL-6 have some redundant activities such as the stimulation of acute phase protein synthesis.
6 Suggesting a role of LIF during hematopoietic malignancies, marrow stromal cells from patients with various hematological neoplasms showed enhanced constitutive LIF expression as compared to stromal cells from normal marrow. 8, 9 Like other cytokines, circulating LIF concentrations could be valuable as a marker of the exacerbation of cytokine 63 leukemic patients before therapy according to the Helsinki recommendations. Twenty patients had a nonlymphoid malig-(78.9 ± 8.9 pg/ml) while they were not significantly different nancy including 12 acute myeloid leukemia (AML) (mean age in patients with CLL (129.5 ± 63.1 pg/ml, P = 0.07) and AML 60 ± 5, sex ratio man/woman 3) and eight refractory anemia (101.8 ± 18.3 pg/ml, P = 0.14). LIF levels were correlated with with excess of blasts (RAEB) (mean age 74 ± 3, sex ratio 7).
M-CSF levels in patients with HL (r = 0.90, P = 0.0001) and Forty-three patients had a lymphoid malignancy including 25 NHL (r = 0.66, P = 0.0004). LIF and IL-6 levels were not correnon-Hodgkin's lymphoma (NHL) (mean age 62 ± 4 years, sex lated except in patients with RAEB (r = 0.86, P = 0.006). LIF ratio 1.5, 12 Hodgkin's lymphoma (HL) (mean age 43 ± 5 and IL-8 levels were not correlated. years, sex ratio 2), and six chronic lymphocytic leukemia
As for other cytokines detected in higher levels in serum (CLL) (mean age 70 ± 2 years, sex ratio 1). Fifty-five healthy during hematologic malignancies, LIF also represents a marker individuals (mean age 60 ± 3 years, sex ratio 1.2) served as of the exacerbation of cytokine production in patients with controls. Serum LIF levels were measured by an enzyme-HL, NHL and RAEB. Despite redundant activities between LIF linked immunosorbent assay (ELISA) for human LIF as preand IL-6 their circulating levels are not correlated. The viously described. 10 Briefly, specific high titer polyclonal antiabsence of correlation between LIF and IL-8 or IL-6 (except bodies obtained by intra-lymph node immunization of rabbits in RAEB) suggests that the cell sources and/or the mechanisms with recombinant LIF have been used to develop specific, of production leading to LIF, IL-8, and IL-6 synthesis differ accurate and sensitive ELISA. The same batch of purified antibetween the different types of hematologic malignancies. The LIF antibodies has been used for the coating of 96-well plates correlations between LIF and M-CSF levels in HL and NHL (capture antibody) and for the quantitative detection of the are difficult to interpret since no information regarding the bound cytokine molecules (soluble biotinylated antibodies).
sources and relationships of production of M-CSF and LIF in The sensitivity (12 pg/ml), accuracy (intra-assay variation these malignancies is available. Our present results strengthen Ͻ20%) and reproducibility (inter-assay variation Ͻ17%) are the putative role of LIF during hematopoietic malignancies equivalent to those for previously published ELISA. 10 Results previously suggested by data reporting the enhanced constitutare expressed as mean ± s.e.m. Comparison between groups ive LIF expression of marrow stromal cells of patients with was made using Mann-Whitney U-test. A P value Ͻ0.05 was various hematological neoplasms as compared with those considered to be significant. Correlations between serum LIF from controls.
8,9
and serum M-CSF, IL-6, and IL-8 concentrations (previously assessed for these patients 1,2 ) were calculated by linear V Lorgeot Laboratoire d'Hématologie Expérimentale regression analysis. V Praloran Faculté de Médecine As shown in Figure 1 , serum concentrations of LIF were sig-P Turlure 2 rue Dr Marcland nificantly higher in patients with HL (297.1 ± 149.5 pg/ml, Y Denizot 87025 Limoges, France P = 0.005), NHL (196.5 ± 48.6 pg/ml, P = 0.003), and RAEB (191.0 ± 68.7 ± pg/ml, P = 0.02) than in control subjects Acknowledgement
